Myriad Genetics reaffirms 2026 guidance amid Q1 earnings miss

Statements (8)

1. ● Neutral

   Myriad Genetics (NASDAQ:MYGN) reported Q1 earnings results

   finance.yahoo.comJun 30, 2026 15:47 UTC
2. ▼ Bearish

   Myriad Genetics missed revenue expectations in Q1 2026

   finance.yahoo.comMay 15, 2026 03:00 UTCHigh importance
3. ▼ Bearish

   Myriad Genetics missed adjusted earnings expectations in Q1 2026

   finance.yahoo.comMay 15, 2026 03:00 UTCHigh importance
4. ● Neutral

   Myriad Genetics posted modest year-over-year sales growth in Q1 2026

   finance.yahoo.comMay 15, 2026 03:00 UTC
5. ● Neutral

   Myriad Genetics reaffirmed full-year 2026 guidance of $860 million to $880 million

   finance.yahoo.comMay 6, 2026 01:35 UTC
6. ● Neutral

   Myriad Genetics plans stepped-up commercial and R&D investment in Q1

   finance.yahoo.comMay 6, 2026 01:35 UTC
7. ▼ Bearish

   Myriad Genetics reported an adjusted EBITDA loss of about $5 million in Q1

   finance.yahoo.comMay 6, 2026 01:35 UTC
8. ● Neutral

   Myriad Genetics retained $199 million in available capital in Q1

   finance.yahoo.comMay 6, 2026 01:35 UTC